Abrégé

The present invention relates to the use of a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating and/or preventing peritoneal dialysis-associated peritoneal fibrosis and/or peritoneal diseases associated therewith. The structure of the compound as represented by the formula (I) is as follows: (I).

Classes IPC  ?

• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61P 35/00 - Agents anticancéreux
• C07D 493/12 - Composés hétérocycliques contenant des atomes d'oxygène comme uniques hétéro-atomes dans le système condensé dans lesquels le système condensé contient trois hétérocycles

Abrégé

The present invention relates to the field of biomedicine, and in particular, to an M protein detection method. The method comprises: 1) providing m/z distribution data of singly-charged ions in immunoglobulin light chains in samples to be detected, the light chains comprising a λ light chain and a κ light chain; and 2) performing result determination: if there is, in the m/z range of the light chains, a mass spectrum peak which has a narrow base and is high and sharp, determining that said samples contain M proteins, or if the peak area ratio of the κ light chain to the λ light chain is less than 1.8 or greater than 3.5, and the peak shape is in a non-Gaussian distribution, determining that said samples contains M proteins.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 27/62 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'ionisation des gaz, p. ex. des aérosolsRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant les décharges électriques, p. ex. l'émission cathodique
• G16B 40/20 - Analyse de données supervisée
• G06F 18/214 - Génération de motifs d'entraînementProcédés de Bootstrapping, p. ex. ”bagging” ou ”boosting”
• G06F 18/2431 - Classes multiples

Abrégé

The present invention relates to use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating and/or preventing renal fibrosis and/or renal diseases related to renal fibrosis. The compound represented by formula (I) has a structure as follows:

Classes IPC  ?

• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins

Abrégé

The present application relates to use of an MDP analog in an inflammatory bowel disease. The MDP analog disclosed herein has a potent anti-inflammatory effect and an inhibitory effect on inflammatory cytokines, and can effectively treat and prevent inflammatory bowel diseases, thus providing a new medication strategy for the clinical treatment of IBD.

Classes IPC  ?

• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques

Abrégé

A use of a tissue transparent method and a histological method in combination for detecting bacteria in a tumor. The combined use of the tissue transparent method and a traditional histological method can break the limitation on the thickness of a sample. A tissue having a thickness of 500 μm is selected, and optical transparency is achieved by using the tissue transparent method. Meanwhile, the traditional histological method is also used to mark bacteria inside a tumor tissue. Thus, potential contamination on the surface of a thin slice is avoided, and a high-resolution and integral three-dimensional image of a large-size tissue sample can be completely constructed, thereby realizing three-dimensional visualization of the bacteria in the tumor, and achieving more accurate experimental results.

Classes IPC  ?

• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 21/64 - FluorescencePhosphorescence

Abrégé

The present application relates to a use of a nitric oxide synthase pathway inhibitor in preparation of a medicine, wherein the medicine is used for preventing, relieving and/or treating gastrointestinal ischemia-reperfusion related distal injury in a subject. The present application further relates to a use of nitric oxide synthase for screening a medicine, wherein the medicine is used for preventing, relieving and/or treating gastrointestinal ischemia-reperfusion related distal injury in a subject. The present application further relates to a pharmaceutical composition containing the nitric oxide synthase pathway inhibitor and a method for preventing, relieving and/or treating gastrointestinal ischemia-reperfusion related distal injury in a subject.

Classes IPC  ?

• A61K 31/155 - Amidines (), p. ex. guanidine (H2N-C(=NH)-NH2), isourée (HN=C(OH)NH2), isothiourée (HN=C(SH)-NH2)
• A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
• A61K 47/00 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale

Abrégé

The present application relates to use of a TLR4 pathway inhibitor and/or antagonist in preparation of a drug, the drug being used for preventing, alleviating and/or treating gastrointestinal ischemia-reperfusion related distal injury in a subject. The present application further relates to use of TLR4 for screening a drug, wherein the drug is used for preventing, alleviating and/or treating gastrointestinal ischemia-reperfusion related distal injury in a subject. The present application further relates to a pharmaceutical composition containing the TLR4 pathway inhibitor and/or antagonist and a method for preventing, alleviating and/or treating gastrointestinal ischemia-reperfusion related distal injury in a subject.

Classes IPC  ?

• A61K 31/7024 - Esters de saccharides
• A61K 31/215 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques
• A61K 31/688 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols les deux composés hydroxylés ayant des atomes d'azote, p. ex. sphingomyélines
• A61K 31/685 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols un des composés hydroxylés ayant des atomes d'azote, p. ex. phosphatidylsérine, lécithine
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The present application relates to a use of a nitric oxide synthase pathway inhibitor in preparation of a medicine, wherein the medicine is used for preventing, relieving and/or treating gastrointestinal ischemia-reperfusion related distal injury in a subject. The present application further relates to a use of nitric oxide synthase for screening a medicine, wherein the medicine is used for preventing, relieving and/or treating gastrointestinal ischemia-reperfusion related distal injury in a subject. The present application further relates to a pharmaceutical composition containing the nitric oxide synthase pathway inhibitor and a method for preventing, relieving and/or treating gastrointestinal ischemia-reperfusion related distal injury in a subject.

Classes IPC  ?

• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61K 31/155 - Amidines (), p. ex. guanidine (H2N-C(=NH)-NH2), isourée (HN=C(OH)NH2), isothiourée (HN=C(SH)-NH2)
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale

Abrégé

The present application relates to the field of medical image processing. Disclosed is an automatic tumor segmentation method and system in a CT image for segmenting a tumor focus area in the CT image and solving the problem that the segmentation precision of the CT image is low. The method comprises: performing data enhancement and expansion on original image data to obtain enhanced and expanded data; performing normalization processing on the enhanced and expanded data to obtain normalized data; inputting the normalized data into a trained processing network to obtain a segmented image; and performing noise reduction processing on the segmented image. Therefore, the differences of different original images caused by scanning of different CT machines are reduced, and the application range and the precision of the processing result of the processing network are improved.

Classes IPC  ?

• G06T 7/11 - Découpage basé sur les zones

Abrégé

A puncture planning path correction method and device, the method comprising: on the basis of an initial planning path, determine an initial entry point on the skin in a puncture region and set the initial entry point as a marker point (201); perform two successive CT scans of the puncture region to obtain an initial CT image and a second CT image (202); mark on the initial CT image an initial planning path; acquire position information of a mark point in the second CT image (203); perform registration on the initial CT image and the second CT image; on the basis of the position information of the marker point, determine the position of the marker point in the initial CT image after registration (204); obtain a distance vector of the marker point to the initial planning path (205); utilizing the distance vector of the marker point to the initial planning path, perform a translation transformation of the initial planning path, and set an intersection point of the transformed path and the puncture region on the skin as an actual entry point; on the basis of the actual entry point, and in accordance with the length of the initial planning path, determine a target point, and obtain a corrected puncture planning path (206). The puncture planning path correction device comprises: a marker point determining unit (401), a CT scanning unit (402), an initialization unit (403), a registration unit (404), a translation vector acquisition unit (405) and a correction unit (406).

Classes IPC  ?

• A61B 34/10 - Planification, simulation ou modélisation assistées par ordinateur d’opérations chirurgicales
• A61B 17/34 - TrocartsAiguilles à ponction

Abrégé

An optimized method for isolating human intestinal probiotics, comprising the following step: step 1, basal culture medium preparation: preparing a mucoprotein liquid culture medium and a mucoprotein solid culture medium; step 2, screening: collecting stool samples and inoculating the mucoprotein liquid culture medium with same, obtaining a bacteria solution by means of anaerobic culture, taking the bacteria solution as a template for carrying out a PCR experiment, selecting the bacteria solution in the tube having a positive result for a PCR reaction and inoculating the mucoprotein solid culture medium with the bacteria solution, obtaining bacterial colonies by means of anaerobic culture, inoculating a chocolate agar plate with the bacterial colonies on the mucoprotein solid culture medium , obtaining bacterial colonies by means of anaerobic culture, inoculating a Columbia blood agar plate with the bacterial colonies on the chocolate agar plate, obtaining bacterial colonies by means of purification and culture, and taking the bacterial colonies on the Columbia blood agar plate to perform PCR sequencing verification by using 16sRNA universal primers, thereby isolating human intestinal probiotics.

Classes IPC  ?

• C12N 1/02 - Séparation des micro-organismes de leurs milieux de culture

Abrégé

Provided in the present invention is a small molecular peptide capable of binding specifically with lung cancer cells; the peptide is a molecule with 8 amino acids containing the structure of XGXG, wherein G is L-glycine and X is one of 20 amino acids. Also provided in the present invention are a small molecular probe obtained by labeling the above-mentioned small molecular peptide with isotope 99mTc, a small molecular radio-therapeutic agent targeting lung cancer obtained after labeling the above-mentioned small molecular peptide with isotope 131I and preparation methods for the above-mentioned probe and therapeutic agent.

Classes IPC  ?

• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• C07K 1/13 - Marquage de peptides
• A61K 51/08 - Peptides, p. ex. protéines
• A61K 101/02 - Halogènes
• A61K 103/00 - Métaux radioactifs
• A61K 103/10 - TechnétiumRhénium
• A61P 35/00 - Agents anticancéreux

Abrégé

An antibacterial fibrous dressing containing nano-sized metal and a preparation method thereof. On the surfaces of the fibers of the dressing are distributed nano-sized metal particles in an amount of 0.5 to 10 wt%. The dressing can persistently release sufficient amounts of nano-sized metal particles to provide long term and effective antibacterial capability, suitable for use as a dressing for chronic wounds.

Classes IPC  ?

• A61L 15/18 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p. ex. serviettes hygiéniques, tampons contenant des matériaux inorganiques
• A61L 15/28 - Polysaccharides ou leurs dérivés
• A61L 15/60 - Matériaux gonflant avec les liquides pour former un gel, p. ex. super-absorbants

Abrégé

A wound dressing with high moisture absorption and capable of being removed as a whole and a preparation method therefor. The wound dressing with high moisture absorption and capable of being removed as a whole comprises crosslinked carboxymethyl solvent-spun cellulose fiber or fabric, and preferably microcrosslinked carboxymethyl solvent-spun cellulose fiber or fabric. A use of the wound dressing in treatment of chronic wounds.

Classes IPC  ?

• A61L 15/28 - Polysaccharides ou leurs dérivés
• A61L 15/46 - Désodorisants ou produits pour neutraliser les mauvaises odeurs, p. ex. pour inhiber la formation d'ammoniac ou la multiplication de bactéries
• A61F 13/02 - Bandages ou pansements adhésifs

Abrégé

An anti-bacterial, moisture absorptive and calcium ion donating wound dressing and a preparation method therefor. The wound dressing comprises chitosan fibers, calcium alginate fibers and chemically modified cellulose fibers. The preparation method comprises blending chitosan fibers, calcium alginate fibers and chemically modified cellulose fibers to obtain a fabric, cutting, packaging, and sterilizing. The wound dressing is useful in treatment of venous stasis ulcers, pressure ulcers, diabetic foot ulcers and other chronic ulcers.

Classes IPC  ?

• A61L 15/28 - Polysaccharides ou leurs dérivés
• A61F 13/02 - Bandages ou pansements adhésifs

Abrégé

A fiber wound dressing having an antibacterial effect and a preparation method therefor. The dressing is a fabric made of fibers having a surface coated with a polyhexamethylene biguanidine solvent or a polyhexamethylene biguanidine solution as an antibacterial agent, wherein the concentration of polyhexamethylene biguanidine coated in the dressing is 400-4000ppm. The fiber wound dressing contains high-concentration polyhexamethylene biguanidine having a broad-spectrum antibacterial effect, is applicable to treatment of a chronic wound, and can be used for consecutive 7 days or longer. The wound dressing has no silver resistance and toxic side effect, and can effectively prevent the infection caused by various bacteria and microorganisms to a wound.

Classes IPC  ?

• A61L 15/46 - Désodorisants ou produits pour neutraliser les mauvaises odeurs, p. ex. pour inhiber la formation d'ammoniac ou la multiplication de bactéries
• A61F 13/00 - Bandages ou pansementsGarnitures absorbantes
• A61L 15/26 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carboneLeurs dérivés
• A61F 13/02 - Bandages ou pansements adhésifs